Valneva shares climbed on Wednesday following the release of final positive immunogenicity and safety data from the Phase 2 trial of its Lyme disease vaccine candidate, VLA15, developed in partnership with Pfizer.
The American pharmaceutical giant will submit marketing authorization applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2026, pending positive results from the Phase 3 study, Valneva said in a statement.
In Paris, at around 08:51 GMT, the stock rose 6.92% to EUR4.05.
According to Mohammed Kaabouni, an analyst at Portzamparc, the results are encouraging, as antibody levels in study participants remained above baseline six months after the third booster dose.
Additionally, no safety or tolerability issues were observed during the trial, he added.
"It is worth noting that the Lyme program accounts for 75% of our valuation. We are maintaining our scenarios," he said.
Analysts at Kempen, meanwhile, stated in a note that they "continue to view the risk/reward profile ahead of the Phase 3 Lyme disease results in the first half of 2026 as highly attractive."
(Written by Etienne Breban, edited by Augustin Turpin)
